Compare Stocks: CNTB, CCCC, ARCT, and OCGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$14.74 -5.7%	$9.29	$5.50 ▼ $24.17	$444.25M	2.48	1.49 million shs	722,953 shs
CCCC C4 Therapeutics	$3.44 -3.1%	$3.86	$1.69 ▼ $5.17	$436.74M	2.94	2.24 million shs	1.44 million shs
CNTB Connect Biopharma	$2.01 +5.2%	$2.26	$1.23 ▼ $3.82	$120.28M	-0.23	931,997 shs	958,713 shs
OCGN Ocugen	$1.07 -19.5%	$1.35	$1.03 ▼ $2.73	$451.02M	2.2	3.19 million shs	39.04 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-1.20%	-3.70%	+110.93%	+126.85%	-12.39%
CCCC C4 Therapeutics	-5.59%	-8.27%	-4.83%	-8.27%	+31.00%
CNTB Connect Biopharma	+3.80%	-19.07%	-13.18%	-8.17%	+6.70%
OCGN Ocugen	-2.21%	0.00%	+4.72%	+11.76%	+29.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$14.74 -5.7%	$9.29	$5.50 ▼ $24.17	$444.25M	2.48	1.49 million shs	722,953 shs
CCCC C4 Therapeutics	$3.44 -3.1%	$3.86	$1.69 ▼ $5.17	$436.74M	2.94	2.24 million shs	1.44 million shs
CNTB Connect Biopharma	$2.01 +5.2%	$2.26	$1.23 ▼ $3.82	$120.28M	-0.23	931,997 shs	958,713 shs
OCGN Ocugen	$1.07 -19.5%	$1.35	$1.03 ▼ $2.73	$451.02M	2.2	3.19 million shs	39.04 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-1.20%	-3.70%	+110.93%	+126.85%	-12.39%
CCCC C4 Therapeutics	-5.59%	-8.27%	-4.83%	-8.27%	+31.00%
CNTB Connect Biopharma	+3.80%	-19.07%	-13.18%	-8.17%	+6.70%
OCGN Ocugen	-2.21%	0.00%	+4.72%	+11.76%	+29.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.60	Moderate Buy	$23.00	56.04% Upside
CCCC C4 Therapeutics	2.60	Moderate Buy	$7.67	122.87% Upside
CNTB Connect Biopharma	2.75	Moderate Buy	$7.43	269.58% Upside
OCGN Ocugen	2.60	Moderate Buy	$9.50	787.85% Upside

Current Analyst Ratings Breakdown

Latest CNTB, CCCC, ARCT, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	ARCT Arcturus Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$41.00
8/14/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/11/2026	OCGN Ocugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CCCC C4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/9/2026	CNTB Connect Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
6/30/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/26/2026	CNTB Connect Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Overweight	$7.00
6/26/2026	CNTB Connect Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Overweight	$7.00
6/25/2026	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$82.03M	5.11	N/A	N/A	$7.53 per share	1.96
CCCC C4 Therapeutics	$35.95M	11.77	N/A	N/A	$2.65 per share	1.30
CNTB Connect Biopharma	$60K	2,109.50	N/A	N/A	$0.75 per share	2.68
OCGN Ocugen	$4.41M	82.28	N/A	N/A	($0.04) per share	-26.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
CCCC C4 Therapeutics	-$104.99M	-$1.00	N/A	N/A	N/A	-289.44%	-45.45%	-30.90%	11/5/2026 (Estimated)
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	11/11/2026 (Estimated)
OCGN Ocugen	-$67.85M	-$0.26	N/A	N/A	N/A	N/A	-127,987.80%	-115.95%	11/4/2026 (Estimated)

Latest CNTB, CCCC, ARCT, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/6/2026	Q2 2026	OCGN Ocugen	-$0.0533	-$0.07	-$0.0167	-$0.07	$0.89 million	$1.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
CCCC C4 Therapeutics	N/A	5.45	5.45
CNTB Connect Biopharma	0.01	2.37	2.37
OCGN Ocugen	4.17	0.80	0.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
CCCC C4 Therapeutics	78.81%
CNTB Connect Biopharma	58.72%
OCGN Ocugen	10.27%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
CCCC C4 Therapeutics	5.60%
CNTB Connect Biopharma	22.60%
OCGN Ocugen	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
CCCC C4 Therapeutics	150	123.03 million	116.14 million	Optionable
CNTB Connect Biopharma	110	62.97 million	48.74 million	Optionable
OCGN Ocugen	80	339.11 million	325.72 million	Optionable

CNTB, CCCC, ARCT, and OCGN Headlines

Recent News About These Companies

Ocugen slips after interim trial data for Stargardt disease candidate

1 hour ago | seekingalpha.com

Ocugen, Inc. (OCGN) Stock Price, News, Quote & History - Yahoo Finance

September 9 at 7:58 AM | finance.yahoo.com

Ocugen, Inc. (NASDAQ:OCGN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 8 at 4:13 AM | marketbeat.com

Bank of America Corp DE Grows Stock Position in Ocugen, Inc. $OCGN

September 3, 2026 | marketbeat.com

OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

September 2, 2026 | zacks.com

OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

September 2, 2026 | finance.yahoo.com

Ocugen Eases on Tests

September 1, 2026 | baystreet.ca

Ocugen Doses First Patient in Global Phase 3 ArMaDa3 Trial of OCU410 for Geographic Atrophy and Receives FDA RMAT Designation

September 1, 2026 | quiverquant.comQ

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

September 1, 2026 | globenewswire.com

27,002,933 Shares in Ocugen, Inc. $OCGN Acquired by BlackRock Inc.

September 1, 2026 | marketbeat.com

Ocugen's September Reckoning: A Fully Funded Pipeline Faces Its First Real Efficacy Test

September 1, 2026 | ad-hoc-news.deA

Ocugen, Inc. (OCGN) Stock Earnings Call Transcripts - Yahoo Finance

August 28, 2026 | finance.yahoo.com

Ocugen to Participate in Upcoming September Investor and Industry Conferences

August 25, 2026 | finance.yahoo.com

Ocugen to Present Modifier Gene Therapy Platform at Upcoming Investor and Industry Conferences in September 2026

August 25, 2026 | quiverquant.comQ

Ocugen to Participate in Upcoming September Investor and Industry Conferences

August 25, 2026 | globenewswire.com

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts

August 15, 2026 | marketbeat.com

Ocugen, Inc. (NASDAQ:OCGN) Receives Average Rating of "Moderate Buy" from Analysts

August 14, 2026 | marketbeat.com

Ocugen (OCGN) Q2 2026 Earnings Call Transcript

August 13, 2026 | fool.com

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Ocugen (OCGN)

August 11, 2026 | theglobeandmail.com

Research Analysts Issue Forecasts for Ocugen Q3 Earnings

August 11, 2026 | marketbeat.com

What is Noble Financial's Forecast for Ocugen Q3 Earnings?

August 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, CCCC, ARCT, and OCGN Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$14.74 -0.89 (-5.69%)

Closing price 04:00 PM Eastern

Extended Trading

$14.68 -0.05 (-0.37%)

As of 07:44 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

C4 Therapeutics NASDAQ:CCCC

$3.44 -0.11 (-3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$3.47 +0.03 (+0.84%)

As of 07:57 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Connect Biopharma NASDAQ:CNTB

$2.01 +0.10 (+5.24%)

Closing price 04:00 PM Eastern

Extended Trading

$2.05 +0.04 (+1.99%)

As of 07:46 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Ocugen NASDAQ:OCGN

$1.07 -0.26 (-19.55%)

Closing price 04:00 PM Eastern

Extended Trading

$1.16 +0.09 (+8.41%)

As of 07:59 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, CCCC, ARCT, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, CCCC, ARCT, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, CCCC, ARCT, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, CCCC, ARCT, and OCGN Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

C4 Therapeutics NASDAQ:CCCC

Connect Biopharma NASDAQ:CNTB

Ocugen NASDAQ:OCGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, CCCC, ARCT, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, CCCC, ARCT, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, CCCC, ARCT, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, CCCC, ARCT, and OCGN Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

C4 Therapeutics NASDAQ:CCCC

Connect Biopharma NASDAQ:CNTB

Ocugen NASDAQ:OCGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools